"InGeNA enables TrakGene to collaborate, create a united voice, align viewpoints and position industry in the evolving conversation and initiatives for the Australian community, helping our organisations grow.

Genomics is seen a core focus for the future of healthcare by the Australian Government, and InGeNA provides a centralised reference point to engage with industry stakeholders, enabling structured and succinct response to initiatives and understanding of future opportunities.”

– Andrew Grant, CEO, TrakGene

"InGeNA membership helps us to keep up to date with initiatives and announcements about genomics from state & federal governments affecting the clinical and industry space, which is really useful in this highly dynamic area. It's important for us to be aware of what's going on, but it can be difficult for us to keep track of the number of announcements, so having InGeNA
monitoring and sharing with members is really useful."

– Mark Crowe - National Research Partnerships Manager, AGRF

“InGeNA is the only organisation convening leaders across medical, pathology and digital health to align priorities and deliver practical solutions for precision medicine implementation in Australia. Its strength lies in coordinated, strategic advocacy that drives the ecosystem change needed to reshape the health system. InGeNA provides the leadership and focus required to implement precision medicine in Australia.”

– Leader Global Pharma member

“InGeNA creates a collaborative environment where challenges across the full scope of precision medicine can be shared. This fosters a broader understanding of integration issues and aligns policy positions, making industry advocacy more efficient. When the precision medicine industry speaks with a unified voice, the Government listens; InGeNA is uniquely placed, through its broad membership, to make this happen.”

– Market Access Lead, Global Pharma member

“Being part of InGeNA provides us with numerous benefits such as amplifying the voice of the genomics industry in a consolidated and united manner to help shape policy and improve healthcare outcomes in Australia. We receive the latest industry news, hear from leading experts in various areas within genomics and collectively work on projects which will educate and inform government and the broader genomics healthcare industry.”

– Oliver Bonaccorso, Precision Medicine and Diagnostics Lead, J&J